Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Fernando Vergara / AP
The Food and Drug Administration designated the drug MDMA, known as Ecstasy, a "breakthrough therapy" for PTSD treatment earlier this month. The designation will expedite the agency's review of the drug, depending on the outcome of a clinical trial to test its effect versus that of standard psychotherapy. Ecstasy is in the DEA's category of Schedule 1 drugs, meaning that it is among substances with the highest potential for abuse, like heroin.
Why it matters: 11-20% of veterans who served in Afghanistan or Iraq suffer from PTSD, per the Department of Veterans' Affairs, and it is this group in particular that researchers hope ecstasy can help.
- "We're in this odd situation where one of the most promising therapies also happens to be a Schedule 1 substance," former Brig. Gen. Loree Sutton said to the Washington Post.
- "This is not a big scientific step ... It's been obvious for 40 years that these drugs are medicine. But it's a huge step in acceptance," David Nutt, a scientist at Imperial College London, told Science.
- One concern is that approving Ecstasy for PTSD will embolden groups seeking to legalize the drug for recreational use, the Post reports.